JP2004509869A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004509869A5 JP2004509869A5 JP2002529069A JP2002529069A JP2004509869A5 JP 2004509869 A5 JP2004509869 A5 JP 2004509869A5 JP 2002529069 A JP2002529069 A JP 2002529069A JP 2002529069 A JP2002529069 A JP 2002529069A JP 2004509869 A5 JP2004509869 A5 JP 2004509869A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- compound according
- diseases
- allergy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 34
- 208000024172 Cardiovascular disease Diseases 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 230000007815 allergy Effects 0.000 description 7
- 208000026935 allergic disease Diseases 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 208000027744 congestion Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 230000008369 airway response Effects 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23403800P | 2000-09-20 | 2000-09-20 | |
| PCT/US2001/029037 WO2002024657A2 (en) | 2000-09-20 | 2001-09-18 | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004509869A JP2004509869A (ja) | 2004-04-02 |
| JP2004509869A5 true JP2004509869A5 (https=) | 2008-09-11 |
Family
ID=22879621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002529069A Pending JP2004509869A (ja) | 2000-09-20 | 2001-09-18 | 二重ヒスタミンｈ１およびｈ３アゴニストまたはアンタゴニストとしての、置換されたイミダゾール |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6528522B2 (https=) |
| EP (1) | EP1318993B1 (https=) |
| JP (1) | JP2004509869A (https=) |
| CN (1) | CN1558907A (https=) |
| AR (1) | AR031612A1 (https=) |
| AT (1) | ATE405557T1 (https=) |
| AU (1) | AU2001291040A1 (https=) |
| CA (1) | CA2422210C (https=) |
| DE (1) | DE60135471D1 (https=) |
| ES (1) | ES2311544T3 (https=) |
| HK (1) | HK1052180A1 (https=) |
| MX (1) | MXPA03002445A (https=) |
| MY (1) | MY120281A (https=) |
| WO (1) | WO2002024657A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| US9796717B2 (en) * | 2013-02-19 | 2017-10-24 | Icahn School Of Medicine At Mount Sinai | Tricyclic heterocycles as anticancer agents |
| US9675587B2 (en) | 2013-03-14 | 2017-06-13 | Allergan Holdings Unlimited Company | Opioid receptor modulator dosage formulations |
| CA2997769A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents |
| EP3347355B1 (en) | 2015-09-09 | 2022-07-13 | Icahn School of Medicine at Mount Sinai | Heterotricyclic sulfonamides as anti-cancer agents |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2586562B1 (fr) | 1985-09-02 | 1989-03-10 | Inst Nat Sante Rech Med | Composition pharmaceutique contenant de l'a-methylhistamine |
| GB8916947D0 (en) | 1989-07-25 | 1989-09-13 | Smith Kline French Lab | Medicaments |
| DE59006842D1 (de) | 1990-03-30 | 1994-09-22 | Heumann Pharma Gmbh & Co | Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung. |
| GB9115740D0 (en) | 1991-07-20 | 1991-09-04 | Smithkline Beecham Plc | Medicaments |
| DK0618905T3 (da) | 1991-12-18 | 1995-12-04 | Schering Corp | Imidazolyl-alkyl-piperazin- og -diazepinderivater som histamin H3-agonister/antagonister |
| US5352707A (en) | 1992-03-26 | 1994-10-04 | Harbor Branch Oceanographic Institution, Inc. | Method for treating airway congestion |
| JPH09505298A (ja) | 1993-11-15 | 1997-05-27 | シェーリング コーポレイション | Ｈ▲下３▼‐レセプターアンタゴニストとしてのフェニル‐アルキルイミダゾール |
| FR2732017B1 (fr) * | 1995-03-21 | 2000-09-22 | Inst Nat Sante Rech Med | Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques |
| EP1019050B1 (en) | 1997-06-24 | 2002-03-20 | Novo Nordisk A/S | Use of somatostatin agonists and antagonists for treating diseases related to the eye |
| US5869479A (en) | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
-
2001
- 2001-09-18 WO PCT/US2001/029037 patent/WO2002024657A2/en not_active Ceased
- 2001-09-18 AT AT01971115T patent/ATE405557T1/de not_active IP Right Cessation
- 2001-09-18 CN CNA018159702A patent/CN1558907A/zh active Pending
- 2001-09-18 AU AU2001291040A patent/AU2001291040A1/en not_active Abandoned
- 2001-09-18 MX MXPA03002445A patent/MXPA03002445A/es active IP Right Grant
- 2001-09-18 MY MYPI20014363A patent/MY120281A/en unknown
- 2001-09-18 JP JP2002529069A patent/JP2004509869A/ja active Pending
- 2001-09-18 ES ES01971115T patent/ES2311544T3/es not_active Expired - Lifetime
- 2001-09-18 CA CA002422210A patent/CA2422210C/en not_active Expired - Fee Related
- 2001-09-18 DE DE60135471T patent/DE60135471D1/de not_active Expired - Lifetime
- 2001-09-18 HK HK03104437.0A patent/HK1052180A1/zh unknown
- 2001-09-18 AR ARP010104400A patent/AR031612A1/es unknown
- 2001-09-18 US US09/954,863 patent/US6528522B2/en not_active Expired - Fee Related
- 2001-09-18 EP EP01971115A patent/EP1318993B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2257393C (en) | Compositions and methods for reducing respiratory depression | |
| JP2007508361A5 (https=) | ||
| JP2006503850A5 (https=) | ||
| JP2006507220A5 (https=) | ||
| JP2008509187A5 (https=) | ||
| JP2003529596A5 (https=) | ||
| JP2002531578A5 (https=) | ||
| JP2005516067A5 (https=) | ||
| JP2009538873A5 (https=) | ||
| SK185399A3 (en) | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION ANDì (54) ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | |
| JP2004525179A5 (https=) | ||
| JP2005525323A5 (https=) | ||
| JP2005525322A5 (https=) | ||
| JP2001521492A (ja) | １−フェニル−４−ベンジルピペラジン：ドーパミン受容体サブタイプ特異性リガンド（ｄ４） | |
| RU2002125495A (ru) | Гидроксифенил-пиперидин-4-илиден-метил-бензамидные производные для лечения боли | |
| JP2003519228A5 (https=) | ||
| JP2004507527A5 (https=) | ||
| JP2002535370A5 (https=) | ||
| RU2003131970A (ru) | Производные 4-(фенил-пиперидин-4-илиден-метил)-бензамида и их применение для лечения боли, тревоги или желудочно-кишечных расстройств | |
| JP2005538974A5 (https=) | ||
| JP2004504308A5 (https=) | ||
| JP2003529597A5 (https=) | ||
| JP2005532397A5 (https=) | ||
| RU2004139041A (ru) | Применение гетероаренкарбоксамидов в качестве дофамин-d3 лигандов для лечения заболеваний центральной нервной системы | |
| JP2006522023A5 (https=) |